Clinical Trials Directory

Trials / Completed

CompletedNCT00903227

Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis

A Proof Of Concept Study To Assess The Steroid Sparing Effect Of Combined Nasal And Inhaled Corticosteroid In Patients With Asthma And Persistent Rhinitis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
25 (actual)
Sponsor
University of Dundee · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Up to 40% of patients with asthma have allergic rhinitis and treatment of nasal airway inflammation with topical steroids improves the twitchiness of the airways (hyperresponsiveness) and overall asthma control. The use of inhaled corticosteroids reduces symptoms, severity of asthma attacks, improves quality of life, and reduces asthma related deaths. Similarly, treatment of rhinitis with nasal steroids reduces symptoms and improves quality of life. While there is evidence that combined treatment of the nose and the lungs with topical steroids improves symptoms and underlying inflammation, it is unclear whether such control can be achieved using a smaller dose of inhaled steroid in combination with nasal steroid. It is therefore the intention of this study to evaluate if combination steroid therapy (nose and lungs) has a steroid sparing effect in patients with asthma and rhinitis using sensitive markers of airway inflammation.

Conditions

Interventions

TypeNameDescription
DRUGFluticasone Evohaler pMDIOne puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
DRUGPlacebo1 puff of inhaled Placebo twice a day
DRUGFluticasone EvohalerOne puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
DRUGPlacebo intranasal sprayplacebo intranasal spray 2 squirts each nostril once a day
DRUGfluticasone propionate (Flixonase®)intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts

Timeline

Start date
2006-12-01
Primary completion
2008-08-01
Completion
2008-08-01
First posted
2009-05-18
Last updated
2019-10-16

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00903227. Inclusion in this directory is not an endorsement.